Leishmaniasis: Current aspects on epidemiology, clinical syndromes, diagnosis, prevention, and treatment

Archives of Hellenic Medicine

Volumn 22, Issue 3, 2005, Pages 239-253

  Tzanetou, K ^a,b  

^a KAT HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Clinical syndromes; Leishmania spp; Leishmaniasis; Treatment

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MILTEFOSINE; PAROMOMYCIN;

DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ENDEMIC DISEASE; GREECE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LEISHMANIA; LEISHMANIASIS; LIFE CYCLE; MORBIDITY; MORTALITY; NONHUMAN; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; REVIEW; SKIN LEISHMANIASIS; STRAIN DIFFERENCE; VECTOR CONTROL; VISCERAL LEISHMANIASIS;

EID: 19944396528     PISSN: 11053992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. DAVIES CR, KAYE P, CROFT SL, SUNDAR S. Leishmaniasis: new approaches to disease control. BMJ 2003, 326:377-382
2. WORLD HEALTH ORGANIZATION. Communicable diseases surveillance and response: geographical distribution, http;// www.who.int
3. KILLICK-KENDRICK R. The life-cycle of Leishmania in the sandfly with special reference to the form infective to the vertebrate host. Ann Parasitol Hum Comp 1990, 65(Suppl 1):37-42
4. LAINSON R, SHAW JJ. Evolution, classification and geographic distribution. In: Peters W, Killick-Kendrick R (eds) The leishmaniases in biology and medicine. Vol I. London, Academic Press, 1987:1-120
5. TZANETOU K. An evaluation of peptidase substrates for isoenzyme characterization of Leishmania spp. M. Sc. Thesis. Parasitology Department, London School of Hygiene and Tropical Medicine, University of London, 1984:1-74
6. RODRIGUEZ N, GUZMAN B, RODAS A, TAKIFF H, BLOOM BR, CONVIT J. Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization. J Clin Microbiol 1994, 32:2246-2252
7. ROBERT-GANGNEUX F, BAIXENCH MT, PIARROUX R, PRATLONG F, TOURTE-SCHAEFER C. Use of molecular tools for the diagnosis and typing of a Leishmania major strain isolated from an HIV-infected patient in Burkina Faso. Trans R Soc Trop Med Hyg 1999, 93:396-397
8. MAGILL AJ, GROGL M, GASSER RA, SUN W, OSTER CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993, 328:1383-1387
9. PEARSON RD, SOUSA AQ. Clinical spectrum of leishmaniasis. Clin Infect Dis 1996, 22:1-13
10. Leishmaniasis. In: Manson's tropical diseases. 18th ed. Bailliere Tindall, London, 1982:93-115
11. REES PH, KAGER PA. Visceral leishmaniasis and post-kala-azar dermal leishmaniasis. In: Peters W, Killick-Kendrick R (eds) The leishmaniases in biology and medicine. Vol II. London, Academic Press, 1987:583-615
12. GRIFFITHS WD. Old world cutaneous leishmaniasis. In: Peters W, Killick-Kendrick R (eds) The leishmaniases in biology and medicine. Vol II. London, Academic Press, 1987:617-636
13. AL-GINDAN Y, OMER AH, AL-HUMAIDAN Y, PETERS W, EVANS DA. A case of mucocutaneous leishmaniasis in Saudi Arabia caused by Leishmania major and its response to treatment. Clin Exp Dermatol 1983, 8:185-188
14. CHULAY JD, BRYCESON AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983, 32:475-479
15. GORGOLAS M. Leishmaniasis. Medicine 1997:32-37
16. EVANS DA. In vitro methods for parasite cultivation. In: Taylor AER, Baker JR (eds) Leishmania. Academic Press, New York, 1987:52-75
17. KRAMPITZ HE, WEILAND G, LOSCHER T, PRUFER L. Evaluation of antigens for the serodiagnosis of kala-azar and oriental sores by means of the indirect immunofluorescence antibody test (IFAT). Infection 1981, 9:264-267
18. MAALEJ IA, CHENIK M, LOUZIR H, BEN SALAH A, BAHLOUL C, AMRI F ET AL. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am J Trop Med Hyg 2003, 68:312-320
19. KUMAR R, PAI K, PATHAK K, SUNDAR S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin Diagn Lab Immunol 2001, 8:1220-1224
20. ZIJLSTRA EE, NUR Y, DESJEUX P, KHALIL EA, EL-HASSAN AM, GROEN J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health 2001, 6:108-113
21. HARITH AE, KOLK AH, KAGER PA, LEEUWENBURG J, MUIGAI R, KIUGU S ET AL. A simple and economical direct agglutination test for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1986, 80:583-536
22. SCHALLIG HD, SCHOONE GJ, KROON CC, HAILU A, CHAPPUIS F, VEEKEN H. Development and application of "simple" diagnostic tools for visceral leishmaniasis. Med Microbiol Immunol 2001, 190:69-71
23. SCHOONE GJ, HAILU A, KROON CC, NIEUWENHUYS JL, SCHALLIG HD, OSKAM L. A fast agglutination screening test (FAST) for the detection of anti-Leishmania antibodies. Trans R Soc Trop Med Hyg 2001, 95:400-401
24. ATTAR ZJ, CHANCE ML, EL-SAFI S, CARNEY J, AZAZY A, EL-HADI M ET AL. Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Trop 2001, 78:11-16
25. GANGNEUX JP, MENOTTI J, LORENZO F, SARFATI C, BLANCHE H, BUI H ET AL. Prospective value of PCR amplification and sequencing for diagnosis and typing of old world Leishmania infections in an area of nonendemicity. J Clin Microbiol 2003, 41:1419-1422
26. MARFURT J, NASEREDDIN A, NIEDERWIESER I, JAFFE CL, BECK HP, FELGER I. Identification and differentiation of Leishmania species in clinical samples by PCR amplification of the miniexon sequence and subsequent restriction fragment length polymorphism analysis. J Clin Microbiol 2003, 41:3147-3153
27. BOSSOLASCO S, GAIERA G, OLCHINI D, GULLETTA M, MARTELLO L, BESTETTI A ET AL. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis J Clin Microbiol 2003, 41:5080-5084
28. VEGA-LOPEZ F. Diagnosis of cutaneous leishmaniasis. Curr Opin Infect Dis 2003, 16:97-101
29. SUNDAR S, MORE DK, SINGH MK, SINGH VP, SHARMA S, MAKHARIA A ET AL. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000, 31:1104-1107
30. BERMAN JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997, 24:684-703
31. DAS VN, RANJAN A, SINHA AN, VERMA N, LAL CS, GUPTA AK ET AL. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India 2001, 49:609-613
32. GRADONI L, BRYCESON A, DESJEUX P. Treatment of mediterranean visceral leishmaniasis. Bull World Health Organ 1995, 73:191-197
33. BERMAN JD. US Food and Drug Administration approval of Ambisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999, 28:49-51
34. SUNDAR S, GUPTA LB, RASTOGI V, AGRAWAL G, MURRAY HW. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000, 94:200-204
35. HERWALDT BL. Leishmaniasis. Lancet 1999, 354:1191-1199
36. PAREDES R, MUNOZ J, DIAZ I, DOMINGO P, GURGUI M, CLOTET B. Leishmaniasis in HIV infection. J Postgrad Med 2003, 49:39-49
37. DE LA ROSA R, PINEDA JA, DELGADO J, MACIAS J, MORILLAS F, MIRA JA ET AL. Incidence and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002, 40:762-767
38. MATHERON S, CABIE A, PARQUIN F, MAYAUD C, ROUX P, ANTOINE M ET AL. Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonar involvement, and effect of secondary prophylaxis. AIDS 1992, 6:238-240
39. LOPEZ-VELEZ R, VIDELA S, MARQUEZ M, BOIX V, JIMENEZ-MEJIAS ME, GORGOLAS M ET AL. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004, 53:540-543